GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operatio...(ber 30 2009 the Company's net loss was $...),Health

Date:11/6/2009

ber 30, 2009, the Company's net loss was $2,440,977 as compared to $2,688,970 in 2008. Net losses for all periods were partially offset by revenues related to the Company's grant from the National Institutes of Health (NIH) in support of its HIV/AIDS vaccine development activities. Grant revenues were $1,808,551 and $3,271,506 for the three and nine month periods ending September 30, 2009, respectively, as compared to $1,322,502 and $2,298,571 for the same periods in 2008. As of September 30, 2009, the Company reported cash balances totaling $3,416,692.

Recent Highlights:

• Effective November 3, 2009, the Company has relocated its corporate headquarters and laboratory operations from the Emtech Bio incubator facility located on the Emory University campus in Atlanta, Georgia to 1900 Lake Park Drive, Suite 380, Smyrna, Georgia, 30080 (metropolitan Atlanta). The move provides additional space for GeoVax's current activities, as well as space to accommodate planned expansion.
• On October 19 - 22, 2009(, )Harriet Robinson, Ph.D., GeoVax's Chief Scientific Officer, attended the AIDS Vaccine 2009 meeting in Paris. This annual meeting is the largest scientific meeting each year devoted to HIV/AIDS vaccines. Dr. Robinson presented a late breaking poster "Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting." Next year, the meeting will be hosted in Atlanta, Georgia where Dr. Robinson will be one of the four local co-organizers.
• On October 15, 2009, GeoVax and Formatech, Inc. announced that GeoVax will be the first recipient of an award under Formatech's "Fillanthropy" program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the vaccine for use in support of GeoVax's HIV/AIDS vaccine clinical trials.
• In September 2009, GeoVax announced that it had requested a p
  '/>"/>

SOURCE GeoVax Labs, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
2. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
3. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
4. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
5. GeoVax Reports Progress on Its AIDS Vaccine Technology
6. GeoVax Secures $10 Million Financing Commitment
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
11. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel